Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)
January 07 2014 - 09:00AM
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty
pharmaceutical company, today announced the issuance of a third
patent (number 8,617,600) by the United States Patent and Trademark
Office (USPTO) covering Oxtellar XR®, its novel once-daily
extended-release oxcarbazepine product. The patent was issued by
the USPTO on December 31, 2013. It provides protection for the
product with expiration that is no earlier than 2027.
"We are committed to building our intellectual property
protection for our products to ensure longevity of our assets. We
now have patent protection on Oxtellar XR® through three issued
U.S. patents and on Trokendi XR™ through two issued U.S. patents,"
said Jack A. Khattar, President and CEO of Supernus.
Supernus has several additional patent applications for
extended-release topiramate and extended-release oxcarbazepine
pending in other geographic regions.
About Oxtellar XR®
Oxtellar XR is the only approved novel once-daily extended
release formulation of oxcarbazepine for the treatment of epilepsy.
It is an antiepileptic drug indicated for adjunctive therapy in the
treatment of partial seizures in adults and in children 6 to 17
years of age. The product is available in 150 mg, 300 mg and 600 mg
extended-release tablets.
For full prescribing and safety information, click
here.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR™
(extended-release oxcarbazepine) and Trokendi XR™ (extended-release
topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in
ADHD, including ADHD patients with impulsive aggression. These
product candidates include SPN-810 for impulsive aggression in ADHD
and SPN-812 for ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding
the potential of Oxtellar XR and Trokendi XR and intellectual
property protection. Actual results may differ materially from
those in these forward-looking statements as a result of various
factors, including, but not limited to, risks regarding the
company's ability to commercialize the product successfully,
whether physicians will prescribe and patients will use the
product, and competition in the market. For a further description
of these and other risks facing the Company, please see the risk
factors described in the Company's Annual Report Form 10-K that was
filed with the United States Securities and Exchange Commission on
March 15, 2013 and under the caption "Risk Factors" and the updates
to these risk factors in the Company's quarterly report form 10-Q
that was filed with the Commission on August 15, 2013.
Forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to update or
revise these statements, except as may be required by law.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2023 to Mar 2024